Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants

Mary Lou Clements-Mann, Robert A Dudas, Yasutaka Hoshino, Pamela Nehring, Ellen Sperber, Mariam Wagner, Ina Stephens, Ruth A Karron, Adamadie Deforest, Albert Z. Kapikian

Research output: Contribution to journalArticle

Abstract

The safety and immunogenicity of an orally administered, live rotavirus vaccine comprised of four strains, each with a titer of 105.3 or 105.8 pfu, and each having 10 genes from the UK bovine strain and the VP7 gene from human rotavirus serotype 1, 2, 3, or 4, were evaluated in adults, young children and infants in randomized, double-blind phase 1 trials. Three doses of rotavirus vaccine or placebo given with childhood immunizations to infants at 2, 4, and 6 months of age were well tolerated and did not inhibit antibody responses to childhood vaccines which included DTP, Hib, hepatitis B and OPV. Serum rotavirus antibody responses were detected in 12 of 20 infants after 1 dose, and in 19/19 of the vaccinees after three doses. Neutralizing antibody responses were detected more often against the bovine rotavirus UK strain (95%) than to human rotavirus VP7 serotypes 1 (37%), 2 (32%), 3 (32%) or 4 (32%). The efficacy of this quadrivalent rotavirus vaccine needs to be evaluated further.

Original languageEnglish (US)
Pages (from-to)4676-4684
Number of pages9
JournalVaccine
Volume19
Issue number32
DOIs
StatePublished - Sep 14 2001

Fingerprint

Rotavirus Vaccines
Rotavirus
childhood
Vaccines
immune response
vaccines
Antibody Formation
Safety
cattle
Haemophilus influenzae type b
Neutralizing Antibodies
Hepatitis B
serotypes
Genes
dosage
Young Adult
Immunization
Placebos
antibodies
hepatitis B

Keywords

  • Diarrheal vaccine
  • Human-bovine reassortant rotavirus vaccine
  • Live attenuated virus vaccine
  • Pediatric vaccine
  • Rotavirus antibody
  • Rotavirus immune responses
  • Rotavirus vaccine
  • Rotavirus vaccine immunity

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. / Clements-Mann, Mary Lou; Dudas, Robert A; Hoshino, Yasutaka; Nehring, Pamela; Sperber, Ellen; Wagner, Mariam; Stephens, Ina; Karron, Ruth A; Deforest, Adamadie; Kapikian, Albert Z.

In: Vaccine, Vol. 19, No. 32, 14.09.2001, p. 4676-4684.

Research output: Contribution to journalArticle

Clements-Mann, Mary Lou ; Dudas, Robert A ; Hoshino, Yasutaka ; Nehring, Pamela ; Sperber, Ellen ; Wagner, Mariam ; Stephens, Ina ; Karron, Ruth A ; Deforest, Adamadie ; Kapikian, Albert Z. / Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. In: Vaccine. 2001 ; Vol. 19, No. 32. pp. 4676-4684.
@article{c01b22ad8d39426cb05e32f6c9a132e7,
title = "Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants",
abstract = "The safety and immunogenicity of an orally administered, live rotavirus vaccine comprised of four strains, each with a titer of 105.3 or 105.8 pfu, and each having 10 genes from the UK bovine strain and the VP7 gene from human rotavirus serotype 1, 2, 3, or 4, were evaluated in adults, young children and infants in randomized, double-blind phase 1 trials. Three doses of rotavirus vaccine or placebo given with childhood immunizations to infants at 2, 4, and 6 months of age were well tolerated and did not inhibit antibody responses to childhood vaccines which included DTP, Hib, hepatitis B and OPV. Serum rotavirus antibody responses were detected in 12 of 20 infants after 1 dose, and in 19/19 of the vaccinees after three doses. Neutralizing antibody responses were detected more often against the bovine rotavirus UK strain (95{\%}) than to human rotavirus VP7 serotypes 1 (37{\%}), 2 (32{\%}), 3 (32{\%}) or 4 (32{\%}). The efficacy of this quadrivalent rotavirus vaccine needs to be evaluated further.",
keywords = "Diarrheal vaccine, Human-bovine reassortant rotavirus vaccine, Live attenuated virus vaccine, Pediatric vaccine, Rotavirus antibody, Rotavirus immune responses, Rotavirus vaccine, Rotavirus vaccine immunity",
author = "Clements-Mann, {Mary Lou} and Dudas, {Robert A} and Yasutaka Hoshino and Pamela Nehring and Ellen Sperber and Mariam Wagner and Ina Stephens and Karron, {Ruth A} and Adamadie Deforest and Kapikian, {Albert Z.}",
year = "2001",
month = "9",
day = "14",
doi = "10.1016/S0264-410X(01)00242-0",
language = "English (US)",
volume = "19",
pages = "4676--4684",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "32",

}

TY - JOUR

T1 - Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants

AU - Clements-Mann, Mary Lou

AU - Dudas, Robert A

AU - Hoshino, Yasutaka

AU - Nehring, Pamela

AU - Sperber, Ellen

AU - Wagner, Mariam

AU - Stephens, Ina

AU - Karron, Ruth A

AU - Deforest, Adamadie

AU - Kapikian, Albert Z.

PY - 2001/9/14

Y1 - 2001/9/14

N2 - The safety and immunogenicity of an orally administered, live rotavirus vaccine comprised of four strains, each with a titer of 105.3 or 105.8 pfu, and each having 10 genes from the UK bovine strain and the VP7 gene from human rotavirus serotype 1, 2, 3, or 4, were evaluated in adults, young children and infants in randomized, double-blind phase 1 trials. Three doses of rotavirus vaccine or placebo given with childhood immunizations to infants at 2, 4, and 6 months of age were well tolerated and did not inhibit antibody responses to childhood vaccines which included DTP, Hib, hepatitis B and OPV. Serum rotavirus antibody responses were detected in 12 of 20 infants after 1 dose, and in 19/19 of the vaccinees after three doses. Neutralizing antibody responses were detected more often against the bovine rotavirus UK strain (95%) than to human rotavirus VP7 serotypes 1 (37%), 2 (32%), 3 (32%) or 4 (32%). The efficacy of this quadrivalent rotavirus vaccine needs to be evaluated further.

AB - The safety and immunogenicity of an orally administered, live rotavirus vaccine comprised of four strains, each with a titer of 105.3 or 105.8 pfu, and each having 10 genes from the UK bovine strain and the VP7 gene from human rotavirus serotype 1, 2, 3, or 4, were evaluated in adults, young children and infants in randomized, double-blind phase 1 trials. Three doses of rotavirus vaccine or placebo given with childhood immunizations to infants at 2, 4, and 6 months of age were well tolerated and did not inhibit antibody responses to childhood vaccines which included DTP, Hib, hepatitis B and OPV. Serum rotavirus antibody responses were detected in 12 of 20 infants after 1 dose, and in 19/19 of the vaccinees after three doses. Neutralizing antibody responses were detected more often against the bovine rotavirus UK strain (95%) than to human rotavirus VP7 serotypes 1 (37%), 2 (32%), 3 (32%) or 4 (32%). The efficacy of this quadrivalent rotavirus vaccine needs to be evaluated further.

KW - Diarrheal vaccine

KW - Human-bovine reassortant rotavirus vaccine

KW - Live attenuated virus vaccine

KW - Pediatric vaccine

KW - Rotavirus antibody

KW - Rotavirus immune responses

KW - Rotavirus vaccine

KW - Rotavirus vaccine immunity

UR - http://www.scopus.com/inward/record.url?scp=0035860598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035860598&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(01)00242-0

DO - 10.1016/S0264-410X(01)00242-0

M3 - Article

C2 - 11535316

AN - SCOPUS:0035860598

VL - 19

SP - 4676

EP - 4684

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 32

ER -